PharmaCyte Biotech Inc (PMCB) - Total Assets
Based on the latest financial reports, PharmaCyte Biotech Inc (PMCB) holds total assets worth $55.98 Million USD as of October 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PharmaCyte Biotech Inc book value and equity for net asset value and shareholders' equity analysis.
PharmaCyte Biotech Inc - Total Assets Trend (2004–2025)
This chart illustrates how PharmaCyte Biotech Inc's total assets have evolved over time, based on quarterly financial data.
PharmaCyte Biotech Inc - Asset Composition Analysis
Current Asset Composition (April 2025)
PharmaCyte Biotech Inc's total assets of $55.98 Million consist of 40.6% current assets and 59.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.5% |
| Accounts Receivable | $3.70 Million | 6.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.55 Million | 2.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how PharmaCyte Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PharmaCyte Biotech Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmaCyte Biotech Inc's current assets represent 40.6% of total assets in 2025, a decrease from 74.4% in 2004.
- Cash Position: Cash and equivalents constituted 27.5% of total assets in 2025, down from 47.6% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 6.7% of total assets.
PharmaCyte Biotech Inc Competitors by Total Assets
Key competitors of PharmaCyte Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
PharmaCyte Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.60 | 4.47 | 4.89 |
| Quick Ratio | 14.60 | 4.47 | 4.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $21.44 Million | $16.56 Million | $2.49 Million |
PharmaCyte Biotech Inc - Advanced Valuation Insights
This section examines the relationship between PharmaCyte Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.22 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -7.9% |
| Total Assets | $55.17 Million |
| Market Capitalization | $7.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values PharmaCyte Biotech Inc's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: PharmaCyte Biotech Inc's assets decreased by 7.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PharmaCyte Biotech Inc (2004–2025)
The table below shows the annual total assets of PharmaCyte Biotech Inc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | $55.17 Million | -7.91% |
| 2024-04-30 | $59.90 Million | -18.25% |
| 2023-04-30 | $73.28 Million | -19.14% |
| 2022-04-30 | $90.62 Million | +1123.95% |
| 2021-04-30 | $7.40 Million | +20.07% |
| 2020-04-30 | $6.17 Million | +6.65% |
| 2019-04-30 | $5.78 Million | -9.83% |
| 2018-04-30 | $6.41 Million | -26.01% |
| 2017-04-30 | $8.67 Million | +21.05% |
| 2016-04-30 | $7.16 Million | -9.92% |
| 2015-04-30 | $7.95 Million | -14.68% |
| 2014-04-30 | $9.32 Million | +223.82% |
| 2013-04-30 | $2.88 Million | +37.82% |
| 2012-04-30 | $2.09 Million | +68.32% |
| 2011-04-30 | $1.24 Million | +3.16% |
| 2010-04-30 | $1.20 Million | -82.43% |
| 2009-04-30 | $6.84 Million | -10.16% |
| 2008-04-30 | $7.62 Million | +72.90% |
| 2007-04-30 | $4.41 Million | -14.23% |
| 2006-04-30 | $5.14 Million | +1426.85% |
| 2005-04-30 | $336.36K | +91.43% |
| 2004-04-30 | $175.71K | -- |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including adv… Read more